Literature DB >> 26622696

Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma.

Pingyu Zhu1, Yongrui Piao2, Xiuzhe Dong2, Zhehu Jin3.   

Abstract

The forkhead box (FOX) family of transcription factors are considered to have a role in tumorigenesis. FOXJ1 is a member of the FOX family; however, its function in human renal cell carcinoma (RCC) has remained to be elucidated. Therefore, the present study evaluated the expression of FOXJ1 in human clear cell RCC and the effect of FOXJ1 on the proliferative ability of RCC cells. The RCC specimens analyzed in the present study were obtained from 286 patients with RCC who underwent nephrectomy. FOXJ1 mRNA expression levels were determined using reverse transcription-quantitative polymerase chain reaction, and FOXJ1 protein expression levels were determined using immunohistochemistry and western blot analysis. To determine the effect of FOXJ1 on the proliferative ability of RCC cells, the expression of FOXJ1 was decreased using small interfering (si)RNA, and a FOXJ1 vector was stably transfected into RCC cell lines. The proliferative ability of RCC cells was then examined using a WST-1 assay and xenograft experiments with BALB/c nude mice, where the association between FOXJ1 expression and patient survival was determined using Kaplan-Meier analysis. FOXJ1 expression was significantly higher in RCC tissues compared with that of healthy renal tissues. Furthermore, FOXJ1 expression was associated with tumor stage, histologic grade and size. In addition, FOXJ1 significantly enhanced the proliferation of RCC cells in vitro and in vivo. The present study identified that FOXJ1 expression was upregulated in RCC and enhanced the proliferative ability of RCC cells. Therefore, FOXJ1 may serve as an independent prognostic marker and a therapeutic target for the treatment of patients with RCC.

Entities:  

Keywords:  forkhead box J1; prognosis; proliferation; renal cell carcinoma; therapeutic target

Year:  2015        PMID: 26622696      PMCID: PMC4533638          DOI: 10.3892/ol.2015.3376

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  46 in total

1.  FoxM1 is required for execution of the mitotic programme and chromosome stability.

Authors:  Jamila Laoukili; Matthijs R H Kooistra; Alexandra Brás; Jos Kauw; Ron M Kerkhoven; Ashby Morrison; Hans Clevers; René H Medema
Journal:  Nat Cell Biol       Date:  2005-01-16       Impact factor: 28.824

Review 2.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

3.  The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration.

Authors:  Xinhe Wang; Hiroaki Kiyokawa; Margaret B Dennewitz; Robert H Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

4.  Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis.

Authors:  Khokon K Dutta; Yumiko Nishinaka; Hiroshi Masutani; Shinya Akatsuka; Than T Aung; Tomoyuki Shirase; Wen-Hua Lee; Yoshihiro Yamada; Hiroshi Hiai; Junji Yodoi; Shinya Toyokuni
Journal:  Lab Invest       Date:  2005-06       Impact factor: 5.662

5.  Application of simplified Fuhrman grading system in clear-cell renal cell carcinoma.

Authors:  Sung K Hong; Chang W Jeong; Ji H Park; Hyung S Kim; Cheol Kwak; Gheeyoung Choe; Hyeon H Kim; Sang E Lee
Journal:  BJU Int       Date:  2010-08-26       Impact factor: 5.588

6.  The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas.

Authors:  Lin Lin; Charles T Miller; Jorge I Contreras; Michael S Prescott; Susan L Dagenais; Rong Wu; John Yee; Mark B Orringer; David E Misek; Samir M Hanash; Thomas W Glover; David G Beer
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

7.  The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.

Authors:  Il-Man Kim; Timothy Ackerson; Sneha Ramakrishna; Maria Tretiakova; I-Ching Wang; Tanya V Kalin; Michael L Major; Galina A Gusarova; Helena M Yoder; Robert H Costa; Vladimir V Kalinichenko
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 8.  Monoclonal antibodies in clinical oncology.

Authors:  S Dalle; C Thieblemont; L Thomas; C Dumontet
Journal:  Anticancer Agents Med Chem       Date:  2008-06       Impact factor: 2.505

Review 9.  Treatment options for metastatic renal cell carcinoma: a review.

Authors:  Uzma Athar; Teresa C Gentile
Journal:  Can J Urol       Date:  2008-04       Impact factor: 1.344

10.  Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study.

Authors:  Samuel Abourbih; Kanishka Sircar; Simon Tanguay; Wassim Kassouf; Armen Aprikian; Jose Mansure; Fadi Brimo
Journal:  World J Surg Oncol       Date:  2013-11-22       Impact factor: 2.754

View more
  4 in total

1.  A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients.

Authors:  Patrick Terrematte; Dhiego Souto Andrade; Josivan Justino; Beatriz Stransky; Daniel Sabino A de Araújo; Adrião D Dória Neto
Journal:  Cancers (Basel)       Date:  2022-04-24       Impact factor: 6.575

2.  Forkhead Box Protein J1 (FOXJ1) is Overexpressed in Colorectal Cancer and Promotes Nuclear Translocation of β-Catenin in SW620 Cells.

Authors:  Kuiliang Liu; Jianghao Fan; Jing Wu
Journal:  Med Sci Monit       Date:  2017-02-17

3.  Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.

Authors:  Seyed Hamidreza Mahmoudpour; Obul Reddy Bandapalli; Miguel Inácio da Silva Filho; Chiara Campo; Kari Hemminki; Hartmut Goldschmidt; Maximilian Merz; Asta Försti
Journal:  BMC Cancer       Date:  2018-08-15       Impact factor: 4.430

Review 4.  Molecular Classification and Therapeutic Targets in Ependymoma.

Authors:  Thomas Larrew; Brian Fabian Saway; Stephen R Lowe; Adriana Olar
Journal:  Cancers (Basel)       Date:  2021-12-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.